Please Wait.....
Report
UK Vaccines Market By Technology Type (Inactivated Vaccines, Toxoid Vaccines, Recombinant and Conjugate Vaccines, Live Attenuated Vaccines, Others) , By Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, and Rubella, Diphtheria, Pertussis, and Tetanus (DTP) , Polio, Hepatitis, Other Indications) By End User (Pediatric, Adults, Travelers) : Opportunity Analysis and Industry Forecast, 2024-2033
Market Report I 2024-11-01 I 150 Pages I Allied Market Research
UK Vaccines Market
The UK vaccines market was valued at $1.4 billion in 2023 and is projected to reach $3.0 billion by 2033, growing at a CAGR of 7.7% from 2024 to 2033.
A vaccine is a biological substance administered to protect individuals against infectious and potentially life-threatening diseases. It contains either the whole or a specific component of viruses, bacteria, or toxins responsible for diseases. Vaccines work by stimulating the immune system to trigger a defense against these pathogens without causing the disease. Key components of a vaccine include antigens, adjuvants, stabilizers, and preservatives. There are various types of vaccines, each designed to stimulate the immune system in different ways, such as inactivated vaccines, subunit vaccines, live attenuated vaccines, toxoid vaccines, and DNA or mRNA vaccines.
Increase in public health campaigns and free immunization initiatives by the National Health Service is a key driver of the UK vaccines market. In addition, rise in awareness among individuals regarding the importance of vaccination, particularly after the COVID-19 pandemic, has propelled the development of the market. A notable trend gaining prominence in the market in recent times is the formation of compound vaccines. These vaccines comprise varying antigens from bacteria, viruses, and other microorganisms, resulting in the development of one formulation offering protection against multiple diseases.
However, the extensive approval process established by the UK Medicines and Healthcare products Regulatory Agency for the commercialization of new vaccines hampers the development of the market. Furthermore, rise in the prevalence of disease variants due to frequent mutations in microorganisms restrains the market growth significantly. On the contrary, rise in the inclination of medical facilities and government in the UK toward developing vaccines for chronic diseases is projected to present remunerative opportunities for the market. For instance, The BMJ-a British publisher of medical journals-states that the UK is poised to become a hotbed of cancer vaccine trials as around 30 British hospitals have signed up to be part of the Cancer Vaccine Launch Pad in 2024.
Segment Review
The UK vaccines market is segmented into technology type, indication, and end user. On the basis of technology type, the market is divided into inactivated vaccines, toxoid vaccines, recombinant & conjugate vaccines, live attenuated vaccines, and others. As per indication, it is classified into pneumococcal disease; influenza; human papilloma virus; meningococcal disease; rotavirus; varicella; measles, mumps, & rubella; diphtheria, pertussis, & tetanus (DTP); polio; hepatitis; and other indications. By end user, it is categorized into pediatric, adults, and travelers.
Key Findings
On the basis of technology type, the recombinant & conjugate vaccines segment was the highest shareholder in 2023.
Depending on indication, the human papilloma virus segment held a notable share of the market in 2023.
As per end user, the pediatric segment dominated the market in 2023.
Competition Analysis
The major players in the global UK vaccines market include Pfizer, Valneva SE, Viatris Inc., AstraZeneca, Emergex Vaccines, Sanofi, Bavarian Nordic A/S, Prokarium, Merck & Co., Inc., and GSK plc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Technology Type
- Inactivated Vaccines
- Toxoid Vaccines
- Recombinant and Conjugate Vaccines
- Live Attenuated Vaccines
- Others
By Indication
- Pneumococcal Disease
- Influenza
- Human Papilloma Virus
- Meningococcal Disease
- Rotavirus
- Varicella
- Measles, Mumps, and Rubella
- Diphtheria, Pertussis, and Tetanus (DTP)
- Polio
- Hepatitis
- Other Indications
By End User
- Pediatric
- Adults
- Travelers
- Key Market Players
- Pfizer
- Valneva SE
- Viatris Inc.
- AstraZeneca
- Emergex Vaccines
- Sanofi
- Bavarian Nordic A/S
- Prokarium
- Merck & Co., Inc.
- GSK plc.
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: UK VACCINES MARKET, BY TECHNOLOGY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Technology Type
4.2. Inactivated Vaccines
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.3. Toxoid Vaccines
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.4. Recombinant And Conjugate Vaccines
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.5. Live Attenuated Vaccines
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.6. Others
4.6.1. Key Market Trends, Growth Factors and Opportunities
CHAPTER 5: UK VACCINES MARKET, BY INDICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Indication
5.2. Pneumococcal Disease
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.3. Influenza
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.4. Human Papilloma Virus
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.5. Meningococcal Disease
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.6. Rotavirus
5.6.1. Key Market Trends, Growth Factors and Opportunities
5.7. Varicella
5.7.1. Key Market Trends, Growth Factors and Opportunities
5.8. Measles, Mumps, And Rubella
5.8.1. Key Market Trends, Growth Factors and Opportunities
5.9. Diphtheria, Pertussis, And Tetanus (DTP)
5.9.1. Key Market Trends, Growth Factors and Opportunities
5.10. Polio
5.10.1. Key Market Trends, Growth Factors and Opportunities
5.11. Hepatitis
5.11.1. Key Market Trends, Growth Factors and Opportunities
5.12. Other Indications
5.12.1. Key Market Trends, Growth Factors and Opportunities
CHAPTER 6: UK VACCINES MARKET, BY END USER
6.1. Market Overview
6.1.1 Market Size and Forecast, By End User
6.2. Pediatric
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.3. Adults
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.4. Travelers
6.4.1. Key Market Trends, Growth Factors and Opportunities
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping Of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning,2023
CHAPTER 8: COMPANY PROFILES
8.1. Pfizer
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Valneva SE
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Viatris Inc.
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. AstraZeneca
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Emergex Vaccines
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Sanofi
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Bavarian Nordic A/S
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Prokarium
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Merck And Co., Inc.
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. GSK Plc.
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. UK VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 2. UK VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 3. UK VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 4. PFIZER: KEY EXECUTIVES
TABLE 5. PFIZER: COMPANY SNAPSHOT
TABLE 6. PFIZER: OPERATING SEGMENTS
TABLE 7. PFIZER: PRODUCT PORTFOLIO
TABLE 8. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 9. VALNEVA SE: KEY EXECUTIVES
TABLE 10. VALNEVA SE: COMPANY SNAPSHOT
TABLE 11. VALNEVA SE: OPERATING SEGMENTS
TABLE 12. VALNEVA SE: PRODUCT PORTFOLIO
TABLE 13. VALNEVA SE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 14. VIATRIS INC.: KEY EXECUTIVES
TABLE 15. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 16. VIATRIS INC.: OPERATING SEGMENTS
TABLE 17. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 18. VIATRIS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 19. ASTRAZENECA: KEY EXECUTIVES
TABLE 20. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 21. ASTRAZENECA: OPERATING SEGMENTS
TABLE 22. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 23. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 24. EMERGEX VACCINES: KEY EXECUTIVES
TABLE 25. EMERGEX VACCINES: COMPANY SNAPSHOT
TABLE 26. EMERGEX VACCINES: OPERATING SEGMENTS
TABLE 27. EMERGEX VACCINES: PRODUCT PORTFOLIO
TABLE 28. EMERGEX VACCINES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 29. SANOFI: KEY EXECUTIVES
TABLE 30. SANOFI: COMPANY SNAPSHOT
TABLE 31. SANOFI: OPERATING SEGMENTS
TABLE 32. SANOFI: PRODUCT PORTFOLIO
TABLE 33. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 34. BAVARIAN NORDIC A/S: KEY EXECUTIVES
TABLE 35. BAVARIAN NORDIC A/S: COMPANY SNAPSHOT
TABLE 36. BAVARIAN NORDIC A/S: OPERATING SEGMENTS
TABLE 37. BAVARIAN NORDIC A/S: PRODUCT PORTFOLIO
TABLE 38. BAVARIAN NORDIC A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 39. PROKARIUM: KEY EXECUTIVES
TABLE 40. PROKARIUM: COMPANY SNAPSHOT
TABLE 41. PROKARIUM: OPERATING SEGMENTS
TABLE 42. PROKARIUM: PRODUCT PORTFOLIO
TABLE 43. PROKARIUM: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 44. MERCK AND CO., INC.: KEY EXECUTIVES
TABLE 45. MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 46. MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 47. MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 48. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 49. GSK PLC.: KEY EXECUTIVES
TABLE 50. GSK PLC.: COMPANY SNAPSHOT
TABLE 51. GSK PLC.: OPERATING SEGMENTS
TABLE 52. GSK PLC.: PRODUCT PORTFOLIO
TABLE 53. GSK PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. UK VACCINES MARKET,2024 - 2033
FIGURE 2. SEGMENTATION OF UK VACCINES MARKET,2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN UK VACCINES MARKET,2024 - 2033
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: UK VACCINES MARKET
FIGURE 10. UK VACCINES MARKET , BY TECHNOLOGY TYPE,2024 - 2033 ($BILLION)
FIGURE 11. UK VACCINES MARKET , BY INDICATION,2024 - 2033 ($BILLION)
FIGURE 12. UK VACCINES MARKET , BY END USER,2024 - 2033 ($BILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: UK VACCINES MARKET
FIGURE 19. TOP PLAYER POSITIONING,2023
FIGURE 20. PFIZER: NET SALES, 2021-2023 ($BILLION)
FIGURE 21. PFIZER: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 22. PFIZER: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 23. VALNEVA SE: NET SALES, 2021-2023 ($BILLION)
FIGURE 24. VALNEVA SE: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 25. VALNEVA SE: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 26. VIATRIS INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 27. VIATRIS INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 28. VIATRIS INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 29. ASTRAZENECA: NET SALES, 2021-2023 ($BILLION)
FIGURE 30. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 31. ASTRAZENECA: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 32. EMERGEX VACCINES: NET SALES, 2021-2023 ($BILLION)
FIGURE 33. EMERGEX VACCINES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 34. EMERGEX VACCINES: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 35. SANOFI: NET SALES, 2021-2023 ($BILLION)
FIGURE 36. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 37. SANOFI: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 38. BAVARIAN NORDIC A/S: NET SALES, 2021-2023 ($BILLION)
FIGURE 39. BAVARIAN NORDIC A/S: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 40. BAVARIAN NORDIC A/S: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 41. PROKARIUM: NET SALES, 2021-2023 ($BILLION)
FIGURE 42. PROKARIUM: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 43. PROKARIUM: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 44. MERCK AND CO., INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 45. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 46. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 47. GSK PLC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 48. GSK PLC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 49. GSK PLC.: REVENUE SHARE, BY REGION, 2023 (%)
LIST OF TABLES
TABLE 1. UK VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 2. UK VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 3. UK VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 4. PFIZER: KEY EXECUTIVES
TABLE 5. PFIZER: COMPANY SNAPSHOT
TABLE 6. PFIZER: OPERATING SEGMENTS
TABLE 7. PFIZER: PRODUCT PORTFOLIO
TABLE 8. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 9. VALNEVA SE: KEY EXECUTIVES
TABLE 10. VALNEVA SE: COMPANY SNAPSHOT
TABLE 11. VALNEVA SE: OPERATING SEGMENTS
TABLE 12. VALNEVA SE: PRODUCT PORTFOLIO
TABLE 13. VALNEVA SE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 14. VIATRIS INC.: KEY EXECUTIVES
TABLE 15. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 16. VIATRIS INC.: OPERATING SEGMENTS
TABLE 17. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 18. VIATRIS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 19. ASTRAZENECA: KEY EXECUTIVES
TABLE 20. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 21. ASTRAZENECA: OPERATING SEGMENTS
TABLE 22. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 23. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 24. EMERGEX VACCINES: KEY EXECUTIVES
TABLE 25. EMERGEX VACCINES: COMPANY SNAPSHOT
TABLE 26. EMERGEX VACCINES: OPERATING SEGMENTS
TABLE 27. EMERGEX VACCINES: PRODUCT PORTFOLIO
TABLE 28. EMERGEX VACCINES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 29. SANOFI: KEY EXECUTIVES
TABLE 30. SANOFI: COMPANY SNAPSHOT
TABLE 31. SANOFI: OPERATING SEGMENTS
TABLE 32. SANOFI: PRODUCT PORTFOLIO
TABLE 33. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 34. BAVARIAN NORDIC A/S: KEY EXECUTIVES
TABLE 35. BAVARIAN NORDIC A/S: COMPANY SNAPSHOT
TABLE 36. BAVARIAN NORDIC A/S: OPERATING SEGMENTS
TABLE 37. BAVARIAN NORDIC A/S: PRODUCT PORTFOLIO
TABLE 38. BAVARIAN NORDIC A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 39. PROKARIUM: KEY EXECUTIVES
TABLE 40. PROKARIUM: COMPANY SNAPSHOT
TABLE 41. PROKARIUM: OPERATING SEGMENTS
TABLE 42. PROKARIUM: PRODUCT PORTFOLIO
TABLE 43. PROKARIUM: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 44. MERCK AND CO., INC.: KEY EXECUTIVES
TABLE 45. MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 46. MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 47. MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 48. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 49. GSK PLC.: KEY EXECUTIVES
TABLE 50. GSK PLC.: COMPANY SNAPSHOT
TABLE 51. GSK PLC.: OPERATING SEGMENTS
TABLE 52. GSK PLC.: PRODUCT PORTFOLIO
TABLE 53. GSK PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. UK VACCINES MARKET,2024 - 2033
FIGURE 2. SEGMENTATION OF UK VACCINES MARKET,2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN UK VACCINES MARKET,2024 - 2033
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: UK VACCINES MARKET
FIGURE 10. UK VACCINES MARKET , BY TECHNOLOGY TYPE,2024 - 2033 ($BILLION)
FIGURE 11. UK VACCINES MARKET , BY INDICATION,2024 - 2033 ($BILLION)
FIGURE 12. UK VACCINES MARKET , BY END USER,2024 - 2033 ($BILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: UK VACCINES MARKET
FIGURE 19. TOP PLAYER POSITIONING,2023
FIGURE 20. PFIZER: NET SALES, 2021-2023 ($BILLION)
FIGURE 21. PFIZER: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 22. PFIZER: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 23. VALNEVA SE: NET SALES, 2021-2023 ($BILLION)
FIGURE 24. VALNEVA SE: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 25. VALNEVA SE: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 26. VIATRIS INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 27. VIATRIS INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 28. VIATRIS INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 29. ASTRAZENECA: NET SALES, 2021-2023 ($BILLION)
FIGURE 30. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 31. ASTRAZENECA: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 32. EMERGEX VACCINES: NET SALES, 2021-2023 ($BILLION)
FIGURE 33. EMERGEX VACCINES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 34. EMERGEX VACCINES: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 35. SANOFI: NET SALES, 2021-2023 ($BILLION)
FIGURE 36. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 37. SANOFI: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 38. BAVARIAN NORDIC A/S: NET SALES, 2021-2023 ($BILLION)
FIGURE 39. BAVARIAN NORDIC A/S: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 40. BAVARIAN NORDIC A/S: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 41. PROKARIUM: NET SALES, 2021-2023 ($BILLION)
FIGURE 42. PROKARIUM: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 43. PROKARIUM: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 44. MERCK AND CO., INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 45. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 46. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 47. GSK PLC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 48. GSK PLC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 49. GSK PLC.: REVENUE SHARE, BY REGION, 2023 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security